Loading
MRG002 is an experimental investigational agent whose form is not stated in the registry from Shanghai Miracogen in phase 3 trials for gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer, with its target not yet stated publicly.
MRG002 is an investigational agent whose form is not stated in the registry developed by Shanghai Miracogen. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05754853 (A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer), in gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer. The largest, NCT05754853, plans to enrol 290 participants with primary completion was scheduled for 2025-10 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.MRG002's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MRG002" OR ABSTRACT:"MRG002") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MRG002, not a curated reading list.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.